Cigna · CGRP mAb Subcutaneous · US health-plan appeal rights

CGRP mAb Subcutaneous denied for failing step therapy by Cigna?

Q: How long do I have to appeal a Cigna CGRP mAb Subcutaneous denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-11

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Cigna typically requires

Cigna's specific coverage criteria for cgrp mab subcutaneous are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Cigna National Formulary Coverage Policy: CGRP Inhibitors / Express Scripts CGRP Step Therapy

The Cigna angle on CGRP mAb Subcutaneous

## Why Cigna Issued a Step-Therapy Denial for Your CGRP Monoclonal Antibody

Step therapy — sometimes called "fail first" — means Cigna requires documented, adequate trials of one or more preferred preventive medications before it will authorize a CGRP monoclonal antibody. Cigna's step-therapy protocol for this drug class typically requires prior trials of established oral preventive agents in categories such as beta-blockers, tricyclic antidepressants, anticonvulsants, or calcium-channel blockers. The plan determined that the submitted PA did not sufficiently document those trials or their outcomes.

## Why This Denial Is Appealable

Step-therapy denials are overturned at a high rate because the required trials have usually already occurred — the documentation was simply incomplete in the original submission. Additionally, federal and many state laws require step-therapy exceptions when: (a) the required medication is contraindicated for the patient, (b) the patient has already tried and failed that step, or (c) the step-therapy requirement would delay necessary treatment for a serious condition. Many states have enacted specific step-therapy override laws that apply to fully insured Cigna plans.

## Your Federal Appeal Rights

ERISA §503 requires a full-and-fair review with written reasoning for self-funded plans.
ACA §2719 external review is available after final internal denial; the window is generally approximately four months.
State step-therapy laws (if your plan is fully insured in a state with such a law) may require Cigna to grant an exception within a specified timeline when statutory criteria are met — check your state insurance department's website.
Expedited review applies when delaying therapy poses a serious health risk.

## Documentation to Gather

Prior preventive medication history: a comprehensive, chronologically ordered list of each required step-therapy agent — drug name, start and stop dates, prescribing physician, reason for discontinuation (inadequate response defined by frequency/severity, intolerance, adverse effect, contraindication). Pharmacy dispensing records are essential corroboration.
Headache diary or functional-impairment records: document migraine frequency and severity during and after each failed preventive trial.
Prescriber medical-necessity letter: summarizes each failed step with dates and outcomes; explains why the patient meets step-therapy exception criteria; references the applicable guideline organization recommending CGRP antibodies for patients who have failed or cannot tolerate standard preventives.
Cigna's step-therapy policy: download the current CGRP step-therapy criteria from cigna.com; the prescriber letter must address every required step in sequence.

## Criteria-Mapping Structure

| Step-Therapy Requirement | Chart Evidence | |---|---| | Adequate trial of required preventive class 1 | Drug name, dates, pharmacy record, outcome note | | Adequate trial of required preventive class 2 | Drug name, dates, pharmacy record, outcome note | | Exception basis (if applicable) | Contraindication, intolerance, or clinical urgency with chart support | | Prescribing specialist documentation | NPI, specialty, board certification if applicable |

Confirm the exact required steps and exception criteria by reading Cigna's current published step-therapy policy and the FDA-approved prescribing label for the CGRP antibody before submitting your appeal.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Cigna appeals

Other insurers on CGRP mAb Subcutaneous

Other denial reasons for Cigna CGRP mAb Subcutaneous

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-11. Editorial standards: denialhelp.com/authors.